Reimagining GSK-3β Therapeutics in Alzheimer's Disease: From Inhibition to Activity Normalization and Targeted Degradation.
Saved in:
| Title: | Reimagining GSK-3β Therapeutics in Alzheimer's Disease: From Inhibition to Activity Normalization and Targeted Degradation. |
|---|---|
| Authors: | Manni E; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakakah, Saudi Arabia., Al-Kuraishy HM; Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriyah University, Baghdad, Iraq., Eisawy R; Department of Biochemistry, Faculty of Veterinary Medicine, Alexandria University, Alexandria, Egypt., Abdelaziz AM; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University-Arish Branch, Arish, 45511, Egypt. ahmed.abdelaziz@su.edu.eg., Batiha GE; Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhur University, Damanhur, AlBeheira, 22511, Egypt. dr_gaber_batiha@vetmed.dmu.edu.eg. |
| Source: | Journal of molecular neuroscience : MN [J Mol Neurosci] 2026 Apr 24; Vol. 76 (2). Date of Electronic Publication: 2026 Apr 24. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Humana Press Country of Publication: United States NLM ID: 9002991 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-1166 (Electronic) Linking ISSN: 08958696 NLM ISO Abbreviation: J Mol Neurosci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1559-1166 |
|---|---|
| DOI: | 10.1007/s12031-026-02518-9 |
